Danish Pharmacovigilance Update, 26 September 2013

21 November 2013

In this issue of Danish Pharmacovigilance Update:

News from the EU

  • Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are associated with risk of capillary leak syndrome
  • Use of bromocriptine (Parlodel®) for prevention or suppression of lactation is to be reassessed
  • Pregnancy prevention programme during treatment with Erivedge
  • Risk of hypermagnesaemia from the use of the parenteral nutrition preparations Numeta G13E and G16E
  • Be aware of the bleeding risk factors associated with the use of the new oral anticoagulants Eliquis®, Pradaxa® and Xarelto®
  • Lariam® and neuropsychiatric adverse reactions
  • Use of short-acting beta-agonists for obstetric indications

News from the Danish Health and Medicines Authority

  • Psychotic or manic symptoms emerging during use of methylphenidate and atomoxetine
  • Adverse reaction reports concerning the HPV vaccine from 1 January through 9 September 2013

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.


...